摘要
目的探讨尤瑞克林和依达拉奉联合应用治疗进展性脑梗死的有效性和安全性。方法研究对象是2013年10月—2014年10月在该院首次接受治疗的68例进展性脑梗死患者。将患者随机分成例数相同的两组。尤瑞克林和依达拉奉用于治疗观察组;舒血宁和依达拉奉用于治疗对照组;对比两组的疗效及不良反应。结果观察组有效率为97.06%,明显高于对照组的76.47%(P<0.05)。观察组的神经功能缺损改善程度明显高于对照组(P<0.05)。观察组的不良反应发生率为11.7%,略高于对照组的8.82%,差异无统计学意义(P>0.05)。结论尤瑞克林和依达拉奉两种药物联合应用治疗进展性脑梗死疗效显著,且安全性好。
Objective To investigate the efficacy and safety of combined application of Yuri Franklin and edaravone in the treatment of progressive cerebral infarction. Methods From October 2013 to October 2014, 68 patients with progressive cerebral infarction patients who were the first time in our hospital was the object. Yurek Lin and edaravone were used in the treatment of observation group. Shuxuening and edaravone were used in the treatment of control group. Then compare the treatment effect and adverse reaction. Results The efficacy of observation group was 97.06%,significantly higher than that of control group 76.47%（P〈0.05）. Neural function defect of observation group improved significantly higher than that of control group（P〈0.05）. The adverse reaction rate in observation group was 11.7%,slightly higher than 8.82% in control group,but no significant difference（P〉0.05）.Conclusion The combined application of Yurek Lin and edaravone in the treatment of progressive cerebral infarction not only has good efficacy but safety.
出处
《中外医疗》
2015年第20期144-145,共2页
China & Foreign Medical Treatment
关键词
尤瑞克林
依达拉奉
进展性脑梗死
Yurek Lin
Edaravone
Progressive cerebral infarction
